SYSTEMIC SCLEROSIS (SSC)

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma that haven't improved with standard treatments. Only 6 adults aged 18-…

This early-stage trial tests a stem cell injection (HS_SW01) in 21 adults with systemic sclerosis, a disease where the immune system attacks the body, causing skin hardening and organ damage. The main goal is to see if the treatment is safe and tolerable. Researchers will also ch…

This early study tests a new drug called HN2302, which aims to create CAR-T cells inside the body to target and control autoimmune diseases like lupus and scleroderma. The trial will enroll 12 adults to check safety and see if the treatment works. It is a first step, so results w…

This early-phase trial will test BCT301, a type of immune cell made from stem cells, in 10 people with severe autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these cells after a short course of chemotherapy. The main goal is to check safe…

This early-phase trial will test the safety and tolerability of a new drug called cizutamig in 10 adults with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. Participants must have moderate to severe skin involvement and have not responded well…

This early-phase trial tests a new drug called GB261 in 10 people with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. The main goal is to check safety and how the body handles the drug. Researchers will also look for early signs that it might …

This study aims to create stem cell lines from blood samples of 16 people: 4 with severe scleroderma, 4 with mild scleroderma, and 8 of their healthy relatives. These stem cells will be turned into various tissue types (like heart, skin, and immune cells) in the lab to study how …

This study will test if blocking a protein called TL1A can reverse skin scarring in systemic sclerosis, a rare autoimmune disease. Researchers will take blood and skin samples from 10 patients with early diffuse scleroderma and 10 healthy people. They will treat the samples in th…

This study looks at a blood protein called FAP, which is linked to tissue scarring and inflammation. Researchers will measure FAP levels in people with rheumatoid arthritis and systemic sclerosis, as well as healthy volunteers, and compare them with standard tests and lung functi…

This study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …